Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Diagnostics Foresees Revenue Increase From DNA Microarray Area

This article was originally published in PharmAsia News

Executive Summary

At a briefing in Tokyo, Roche Diagnostics Japan President Wataru Ogawa said he foresees a revenue of ¥4.1 billion ($38.2 million), a 24 percent increase in its Applied Science business. He said ¥0.5 billion ($4.63 million) will come from new entrants such as DNA microarrays. Ogawa also anticipates a strong demand for point-of-care testing devices in time for a new health guidance that takes effect in April. Roche Diagnostics plans on launching 12 new products in 2008, including high sensitivity DNA microarrays and real-time cell analysis systems. (Click for more-Japanese language

You may also be interested in...



FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

The Quality Lowdown: US FDA Finding New Crop Of Data Integrity Problems

Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel